Debra Frye

4.3k total citations · 2 hit papers
36 papers, 3.2k citations indexed

About

Debra Frye is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Debra Frye has authored 36 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 16 papers in Cancer Research and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Debra Frye's work include Cancer Treatment and Pharmacology (22 papers), Breast Cancer Treatment Studies (14 papers) and HER2/EGFR in Cancer Research (7 papers). Debra Frye is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Breast Cancer Treatment Studies (14 papers) and HER2/EGFR in Cancer Research (7 papers). Debra Frye collaborates with scholars based in United States, United Kingdom and Türkiye. Debra Frye's co-authors include Gabriel N. Hortobágyi, Aman U. Buzdar, Richard L. Theriault, Daniel J. Booser, Frankie A. Holmes, Ronald S. Walters, Nuhad K. Ibrahim, Martin N. Raber, S. Eva Singletary and Arthur Forman and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Debra Frye

36 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

2005 867 citations Aman U. Buzdar, Nuhad K. Ibrahim et al. Journal of Clinical Oncology profile →
THE IMPACT OF NATIONAL CANCER ACT

1991 712 citations Frankie A. Holmes, Ronald S. Walters et al. JNCI Journal of the National Cancer Institute profile →

Peers

Debra Frye

ONCOL

PFM

RNMI

G. N. Hortobágyi United States

Lynda Sawyer United States

Yasuaki Sagara Japan

A. U. Buzdar United States

In Ae Park South Korea

Carolyn I. Sartor United States

Stacy L. Moulder United States

Carla I. Falkson United States

Carl‐Magnus Rudenstam Sweden

Edward G. Mansour United States

G. N. Hortobágyi United States

Debra Frye

1.7k ×0.7

ONCOL

962 ×0.6

311 ×0.6

PFM

573 ×1.1

253 ×0.5

RNMI

Citations per year, relative to Debra Frye Debra Frye (= 1×) peers G. N. Hortobágyi

Countries citing papers authored by Debra Frye

Since Specialization

Citations

This map shows the geographic impact of Debra Frye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra Frye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra Frye more than expected).

Fields of papers citing papers by Debra Frye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra Frye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra Frye. The network helps show where Debra Frye may publish in the future.

Co-authorship network of co-authors of Debra Frye

This figure shows the co-authorship network connecting the top 25 collaborators of Debra Frye. A scholar is included among the top collaborators of Debra Frye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra Frye. Debra Frye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frye, Debra, et al.. (2010). Recommendations for Enhancing Clinical Trials Education: a Review of the Literature. Journal of Cancer Education. 26(1). 64–71. 15 indexed citations

Frye, Debra. (2009). Capecitabine-Based Combination Therapy for Breast Cancer: Implications for Nurses. Oncology nursing forum. 36(1). 105–113. 3 indexed citations

Frye, Debra, Suzanne M. Mahon, & Frances M. Palmieri. (2009). New Options for Metastatic Breast Cancer. Clinical journal of oncology nursing. 13(0). 11–18. 5 indexed citations

Frye, Debra. (2009). Advances in breast cancer treatment: the emerging role of ixabepilone. Expert Review of Anticancer Therapy. 10(1). 23–32. 7 indexed citations

Frye, Debra. (2006). Taxane Chemotherapy—Advances in Treatment for Breast Cancer. 0(1). 40–40. 1 indexed citations

Buzdar, Aman U., Nuhad K. Ibrahim, Daniel J. Booser, et al.. (2005). Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer. Journal of Clinical Oncology. 23(16). 3676–3685. 867 indexed citations breakdown →

Ibrahim, Nuhad K., Zia Ur Rahman, Vicente Valero, et al.. (2002). Phase I Study of Vinorelbine and Docetaxel with Granulocyte Colony-Stimulating Factor Support in the Treatment of Metastatic Breast Cancer. Cancer Investigation. 20(1). 29–37. 11 indexed citations

Rivera, Edgardo, Vicente Valero, Massimo Cristofanilli, et al.. (2002). Phase I study of eniluracil and oral 5‐fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. Cancer. 94(9). 2321–2326. 1 indexed citations

Hortobagyi, Gabriel N., Aman U. Buzdar, Richard L. Theriault, et al.. (2000). Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. JNCI Journal of the National Cancer Institute. 92(3). 225–233. 126 indexed citations

10.

Hoff, Paulo M., Vicente Valero, Aman U. Buzdar, et al.. (2000). Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer. 88(9). 2054–2060. 24 indexed citations

11.

Ibrahim, Nuhad K., Gabriel N. Hortobágyi, Michael S. Ewer, et al.. (1999). Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemotherapy and Pharmacology. 43(6). 471–478. 37 indexed citations

12.

Holmes, Frankie A., et al.. (1997). Secondary drug resistance in breast cancer: Failure to reverse with oral nifedipine. International Journal of Cancer. 73(2). 184–186. 4 indexed citations

13.

Kinney, Anita Y., Ayşegül A. Şahin, Sally W. Vernon, et al.. (1997). The prognostic significance of sialyl-tn Antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer. 80(12). 2240–2249. 41 indexed citations

14.

Ibrahim, Nuhad K., Debra Frye, Aman U. Buzdar, Ronald S. Walters, & Gabriel N. Hortobágyi. (1996). Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.. PubMed. 156(8). 882–8. 68 indexed citations

15.

Resnick, Jeffrey M., Nour Sneige, Bonnie L. Kemp, et al.. (1995). p53 and c-erbB-2 expression and response to preoperative chemotherapy in locally advanced breast carcinoma. Breast Disease. 8(2). 149–158. 8 indexed citations

16.

Walters, Ronald S., Debra Frye, Aman U. Buzdar, Frankie A. Holmes, & Gabriel N. Hortobágyi. (1992). A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer. 69(2). 476–481. 18 indexed citations

17.

Buzdar, Aman U., et al.. (1991). Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Research and Treatment. 18(3). 165–170. 22 indexed citations

18.

Ro, Jungsil, Adel K. El‐Naggar, Jae Y. Ro, et al.. (1989). c-erbB-2 amplification in node-negative human breast cancer.. PubMed. 49(24 Pt 1). 6941–4. 105 indexed citations

19.

Hortobágyi, Gabriel N., Aman U. Buzdar, Debra Frye, et al.. (1987). Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer a prospective, randomized trial. Cancer. 60(11). 2596–2604. 11 indexed citations

20.

Hortobágyi, Gabriel N., et al.. (1986). Phase I clinical study of nafazatrom. Investigational New Drugs. 4(3). 251–255. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact